Quantumzyme Corp. (OTC: QTZM), a biotransformation company specializing in sustainable pharmaceutical manufacturing, released its corporate update for 2025 and outlined its strategic priorities for 2026. The company reported advancements in enzyme research and development, intellectual property activities, and an expanded focus on artificial intelligence and computational methods to support its enzyme engineering efforts. Additionally, the board approved a proposal to change the company’s legal name to Quantum Genesis AI Corp., reflecting a greater emphasis on computational approaches, subject to FINRA approval and expected in the first quarter of 2026.
During 2025, Quantumzyme continued to operate as an early-stage biotechnology company, concentrating on enzyme research for sustainable chemistry applications. Key accomplishments included developing regulatory reporting practices, advancing research on enzyme engineering and biocatalytic processes for pharmaceutical and specialty chemicals, and publishing U.S. and international patent applications for enzymatic processes. The company also updated its corporate website and communications to better articulate its business focus. Throughout the year, Quantumzyme maintained a disciplined approach to capital and regulatory compliance, navigating typical challenges of early-stage biotech development.
A significant development in 2025 was the expansion of AI and computational research. The company began integrating machine learning techniques and computational modeling into its enzyme discovery and structure-function analysis, aiming to improve experimental design and data analysis efficiency. These AI initiatives remain exploratory and focused on internal decision support, with no commercial software development planned. Quantumzyme believes that combining computational methods with laboratory research may guide future development, but acknowledges technical, financial, and operational risks.
The proposed name change to Quantum Genesis AI Corp. underscores the company’s strategic shift toward data-driven enzyme research. The company has submitted documentation for the change, which requires FINRA approval and other regulatory clearances. While the change is expected in Q1 2026, there is no guarantee of timing or approval.
Looking ahead to 2026, Quantumzyme outlined several priorities: advancing enzyme candidates and biocatalytic pathways through internal testing and optimization; refining computational modeling and AI tools to support research; exploring potential collaborations or licensing opportunities with pharmaceutical and chemical companies; increasing visibility through scientific forums and investor communications; and assessing long-term corporate objectives, including reporting status and capital planning. The company cautioned that these objectives are subject to risks such as technical challenges, capital availability, and market conditions.
For more information, visit Quantumzyme's website and the company's profile on OTC Markets.
